tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

XLO Stock Latest News

Xilio Therapeutics Enhances Board with Two New Directors
Company AnnouncementsXilio Therapeutics Enhances Board with Two New Directors
1M ago
8K
XLO
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
PremiumPress Releases
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
1M ago
XLO
Xilio Therapeutics expects cash to fund operations into Q2 of 2025
PremiumThe Fly
Xilio Therapeutics expects cash to fund operations into Q2 of 2025
2M ago
XLO
GILD
Xilio Therapeutics reports Q1 EPS (62c) vs (83c) last year
PremiumThe Fly
Xilio Therapeutics reports Q1 EPS (62c) vs (83c) last year
2M ago
XLO
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
PremiumPress Releases
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
2M ago
XLO
Xilio Therapeutics files to sell 17.58M shares of common stock for holders
PremiumThe FlyXilio Therapeutics files to sell 17.58M shares of common stock for holders
3M ago
XLO
Fly Insider: Xilio, Aerovate among week’s notable insider trades
PremiumThe Fly
Fly Insider: Xilio, Aerovate among week’s notable insider trades
4M ago
XLO
ALDX
Xilio Therapeutics reports Q4 EPS (64c), consensus (64c)
PremiumThe Fly
Xilio Therapeutics reports Q4 EPS (64c), consensus (64c)
4M ago
XLO
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
PremiumPress Releases
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
4M ago
XLO
Xilio Therapeutics Strikes Lucrative Deal with Gilead Sciences
PremiumCompany Announcements
Xilio Therapeutics Strikes Lucrative Deal with Gilead Sciences
4M ago
8K
XLO
Gilead sees FY24 EPS reduction of 3c-4c from Xilio Therapeutics deal
PremiumThe Fly
Gilead sees FY24 EPS reduction of 3c-4c from Xilio Therapeutics deal
4M ago
XLO
GILD
Xilio Therapeutics, Gilead announce exclusive license agreement for XTX301
PremiumThe Fly
Xilio Therapeutics, Gilead announce exclusive license agreement for XTX301
4M ago
XLO
GILD
Xilio Therapeutics announces $11.3M private placement equity financing
PremiumThe FlyXilio Therapeutics announces $11.3M private placement equity financing
4M ago
XLO
Xilio to get $43.5M upfront in pact with Gilead to develop/commercialize XTX301
PremiumThe Fly
Xilio to get $43.5M upfront in pact with Gilead to develop/commercialize XTX301
4M ago
XLO
GILD
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
PremiumPress Releases
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
4M ago
XLO
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
PremiumPress Releases
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
5M ago
XLO
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
PremiumPress Releases
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
6M ago
XLO
Xilio Therapeutics sees advances across clinical pipeline, announces XTX30 data
PremiumThe Fly
Xilio Therapeutics sees advances across clinical pipeline, announces XTX30 data
7M ago
XLO
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
PremiumPress Releases
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
7M ago
XLO
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
PremiumPress ReleasesXilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
8M ago
XLO
Xilio Therapeutics initiates enrollment for Phase 1 combination trial of XTX101
PremiumThe Fly
Xilio Therapeutics initiates enrollment for Phase 1 combination trial of XTX101
8M ago
XLO
Xilio Therapeutics reports Q3 EPS (61c), consensus (81c)
PremiumThe Fly
Xilio Therapeutics reports Q3 EPS (61c), consensus (81c)
9M ago
XLO

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >